Targeted therapies in gynecologic cancers and melanoma

Eugenia Ortega, Rosa Maria Marti, Andree Yeramian, Anabel Sorolla, Xavier Dolcet, David Llobet, Leandro Abal, Maria Santacana, Judit Pallares, Antonio Llombart-Cussac, Xavier Matias-Guiu

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)


The article reviews the main molecular pathology alterations of endometrial and ovarian carcinomas and melanoma. Several promising drugs targeting the genes most frequently altered in these tumors are under consideration. The most promising signaling pathways to be targeted for therapies in these tumors are the tyrosine kinase receptor (EGFR, HER2, c-KIT), the RAS/B-RAF/MAPK, the PI3K-mTOR, and apoptosis signaling pathways. (C) 2008 Elsevier Inc. All rights reserved.

Original languageEnglish
Pages (from-to)262-273
Number of pages12
JournalSeminars in Diagnostic Pathology
Issue number4
Publication statusPublished - Nov 2008


Dive into the research topics of 'Targeted therapies in gynecologic cancers and melanoma'. Together they form a unique fingerprint.

Cite this